Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mundipharma Laboratories GMBH

Division of Mundipharma International Corp. Ltd.

Latest From Renovis Inc.

Colby Pharmaceutical Co.

Colby Pharmaceutical aims to develop drugs capable of inhibiting key enzymatic and hormonal signaling pathways in prostate and brain cancers. The start-up hopes to help men who have been diagnosed with primary or recurrent prostate cancer, including those who have failed current standard of care hormone therapy or chemotherapy. The company's lead compound is an anti-inflammatory and anti-androgenic small molecule that binds the androgen receptor. In culture and in animals, Colby says that it is therapeutic for androgen-dependent prostate tumors. The molecule does not appear to be pro-estrogenic and CPC-100 is also therapeutic for androgen-independent prostate tumors-which would distinguish it from all other anti-androgens now on the market.

Pfizer's Increasingly Specialist Focus

Pfizer's brand-new oncology business unit appears to be the linchpin in its transformation from primary care behemoth to specialty powerhouse. The Big Pharma also followed this up with the announcement that it was cutting early-stage R&D programs focused on obesity, bone health, and what has been its mainstay--cardiovascular disease. Together, these moves should be viewed as the most extreme example of the industry's flight from primary care medicine into the safer haven of specialty-focused pharmaceuticals,
BioPharmaceutical Strategy

Take Me Out To the Public Markets: Device VCs Swing Big Bats

Medical device investors see the potential for significant returns from the recent spate of initial public offerings, and they're tending to outperform their biopharmaceutical counterparts.
Business Strategies

NeuroPharma AB

There is presently no treatment specifically approved to halt the neurological damage that continues for hours and days in the wake of a brain injury. But there is an already-approved compound that some scientists and clinicians believe will prove helpful. The backers of NeuroPharma are betting that a new formulation of cyclosporin, the drug long used to prevent rejection of transplanted organs, can be shown to have a beneficial effect on people with TBI.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Mundipharma AG
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Mundipharma International Corp. Ltd.
  • Senior Management
  • Antony Mattessich, Mng. Dir.
  • Contact Info
  • Mundipharma Laboratories GMBH
    Phone: (41) 61 205 11 12
    St Alban-Rheinweg 74
    Basel, CH-4020